×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ZLAB – zai lab limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ZLAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
07:36 am
zlab
Zai Lab Announces Participation in Investor Conference in January 2025 [Yahoo! Finance]
Medium
Report
Zai Lab Announces Participation in Investor Conference in January 2025 [Yahoo! Finance]
12/12
07:30 am
zlab
Zai Lab Announces Participation in Investor Conference in January 2025
Medium
Report
Zai Lab Announces Participation in Investor Conference in January 2025
12/5
04:43 am
zlab
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? [Yahoo! Finance]
Low
Report
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? [Yahoo! Finance]
12/2
01:32 pm
zlab
Novocure seeks approval after pancreatic cancer wearable scores at Phase III [Yahoo! Finance]
Low
Report
Novocure seeks approval after pancreatic cancer wearable scores at Phase III [Yahoo! Finance]
12/2
10:17 am
zlab
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients [Yahoo! Finance]
Low
Report
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients [Yahoo! Finance]
12/2
07:09 am
zlab
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer [Yahoo! Finance]
Low
Report
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer [Yahoo! Finance]
12/2
07:02 am
zlab
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Low
Report
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
11/27
11:10 pm
zlab
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List [Yahoo! Finance]
Low
Report
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/13
04:47 pm
zlab
Form 4 Zai Lab Ltd For: Dec 11 Filed by: Du Ying
Low
Report
Form 4 Zai Lab Ltd For: Dec 11 Filed by: Du Ying
11/15
05:24 pm
zlab
Form 8-K Zai Lab Ltd For: Nov 14
Medium
Report
Form 8-K Zai Lab Ltd For: Nov 14
11/14
11:12 am
zlab
Form SC 13G Zai Lab Ltd Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SC 13G Zai Lab Ltd Filed by: JANUS HENDERSON GROUP PLC
11/13
04:06 pm
zlab
Form 8-K Zai Lab Ltd For: Nov 13
High
Report
Form 8-K Zai Lab Ltd For: Nov 13
11/12
09:44 am
zlab
Form 10-Q Zai Lab Ltd For: Sep 30
Low
Report
Form 10-Q Zai Lab Ltd For: Sep 30
11/12
09:33 am
zlab
Form 8-K Zai Lab Ltd For: Nov 12
Low
Report
Form 8-K Zai Lab Ltd For: Nov 12
11/8
10:53 am
zlab
Form SC 13G/A Zai Lab Ltd Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A Zai Lab Ltd Filed by: WELLINGTON MANAGEMENT GROUP LLP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/23
Form 6-K Zai Lab Ltd For: Jan 22
14.5%
10/30 Zai Lab Announces Upcoming Presentations at November Conferences 12.5%
1/14 Zai Lab Appoints Lonnie Moulder to Board of Directors 9.3%
9/4 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. 6.7%
5/6 Form 424B2 Zai Lab Ltd 5.5%
12/27 Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer 5.3%
10/25 Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer 5.2%
1/12 Week In Review: 4 China Biopharmas Announce $100+ Million Deals In First Week Of 2020 [Seeking Alpha] 5.0%
4/8 Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) 5.0%
2/10 Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA 5.0%
10/30 Zai Lab Announces Upcoming Presentations at November Conferences 12.5%
1/14 Zai Lab Appoints Lonnie Moulder to Board of Directors 9.3%
9/4 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at China Renaissance Securities Ltd.. They set a "buy" rating on the stock. 6.7%
5/6 Form 424B2 Zai Lab Ltd 5.5%
12/27 Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer 5.3%
10/25 Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer 5.2%
1/12 Week In Review: 4 China Biopharmas Announce $100+ Million Deals In First Week Of 2020 [Seeking Alpha] 5.0%
4/8 Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody) 5.0%
2/10 Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA 5.0%
TOP News Decliners
3/16
Form 6-K Zai Lab Ltd For: Mar 16
-12.6%
8/27 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.4%
12/16 Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board -6.0%
1/21 Form POSASR Zai Lab Ltd -5.8%
5/16 Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections -4.8%
4/30 Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference -4.5%
8/12 China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China -3.7%
3/19 Zai Lab's (ZLAB) CEO Samantha Du on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -3.2%
6/28 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -2.6%
4/27 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -2.1%
8/27 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.4%
12/16 Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board -6.0%
1/21 Form POSASR Zai Lab Ltd -5.8%
5/16 Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections -4.8%
4/30 Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference -4.5%
8/12 China National Medical Products Administration Grants Innovative Medical Device Designation for Optune® in China -3.7%
3/19 Zai Lab's (ZLAB) CEO Samantha Du on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -3.2%
6/28 Zai Lab Ltd (NASDAQ: ZLAB) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -2.6%
4/27 Zai Lab Ltd (NASDAQ: ZLAB) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -2.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: